B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human
B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human

Immobilized B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-B7-H3 Antibody, hFc Tag with the EC50 of 65.6 ng/ml determined by ELISA.

B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human

The purity of B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human) is greater than 95% as determined by SEC-HPLC.

B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human

B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human

B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers.B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig‑B7‑H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.
Z03891
¥223,852.00

Ask us a question
Product Introduction
Species Human
Protein Construction
B7-H3 (4Ig) /B7-H3b (Gly27-Thr461)
Accession # Q5ZPR3-1		 hFc
N-term C-term
Conjugate FITC
Purity > 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Immobilized B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human (Cat.No.: Z03891) at 1 μg/ml (100μl/Well) on the plate can bind Biotinylated Anti-B7-H3 Antibody, hFc Tag
Expression System HEK293
Theoretical Molecular Weight 73.4 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 90-110 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4.
Reconstitution It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O more than 100 μg/ml.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human
    • B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human

    Immobilized B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Biotinylated Anti-B7-H3 Antibody, hFc Tag with the EC50 of 65.6 ng/ml determined by ELISA.

  • B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human
    • B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human

    The purity of B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human) is greater than 95% as determined by SEC-HPLC.

  • B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human
    • B7-H3 (4Ig) /B7-H3b HFc Chimera[FITC], Human

    B7-H3 (4Ig) /B7-H3b hFc Chimera[FITC], Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background B7-H3, a member of the B7 family of immunomodulatory molecules, is overexpressed in a wide range of solid cancers.B7-H3 binds to activated T cells via an as yet unidentified receptor. In assays using sub-optimal amount so anti-CD3 stimulation, 2Ig‑B7‑H3 enhances T cell proliferation, T cell interferon-gamma (IFN-gamma) production, and cytotoxic T cells induction.
Synonyms B7-H3; CD276; PSEC0249; 4Ig-B7-H3; UNQ309; PRO352; B7 homolog 3; CD276

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.